Sign in
TerminatedNo phase

Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Key facts

Who runs it
M.D. Anderson Cancer Center
Where
Houston, United StatesSee the site
Trial code
Status
Terminated
People taking part
27 people enrolled
Started
15 Aug 2022
Ended
21 Aug 2024
Type of study
Observational
Treatments tested
  • Behavioral Assessment
  • Electronic Health Record Review
Record updated
26 August 2024
Why it stopped
IRB Study Closure

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Patients with pathologically confirmed breast cancer with any receptor status, who will receive neoadjuvant chemotherapy. Patients with denovo oligo-metastatic disease, where the intent of therapy is curative with incorporation of local therapy (surgery/radiation to the breast and/or metastatic sites) are also eligible
  • Age >= 18 years
  • Ability to understand and the willingness to sign a written informed consent
  • Willingness to wear sensors to track physical activity, global positioning system (GPS) location, and provide symptom ratings each night during the screening period of their clinical trial and 180 days after starting treatments
  • Able to read English, Spanish, or Mandarin to complete patient reported outcomes
  • Able to ambulate without an assistive device

Who cannot take part

  • Known movement disorder such as Parkinson's disease, choreo-athetoid movement disorders, essential tremor if that movement disorder is of sufficient severity to require drug therapy
  • Missing lower limbs

Where in United States

  • M D Anderson Cancer CenterHouston, United States

About the trial

What the trial wants to find out

This study assesses the performance status in stage I-III triple negative breast cancer patients who are receiving neoadjuvant chemotherapy. Information collected in this study may help doctors learn if movement and fitness trackers can be used to predict side effects in cancer patients receiving chemotherapy.

The group in the trial

  • Observational (movement assessment, medical data collection)

    Patients complete movement assessment 5-15 days prior to the initiation of neoadjuvant chemotherapy and at day 1 of neoadjuvant chemotherapy. Patients' SAE data is collected. Patients are observed during their neoadjuvant chemotherapy for up to 6 months.

    Treatment: Behavioral Assessment and Electronic Health Record Review

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
26 August 2024